Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | TRPM8 | Q7Z2W7 | 11/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.45 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6122175 | 1.00 | POLB (0.47) | POLBTDP1TRPM8CHRM2CHRM1 | |
| SCHEMBL6123150 | 0.86 | POLB (0.47) | POLBTDP1TRPM8CHRM2CHRM1 | |
| SCHEMBL14143063 | 0.84 | CHRM2 (0.45) | POLBTDP1TRPM8CHRM2CHRM1 | |
| SCHEMBL21114755 | 0.81 | TSHR (0.45) | POLBTDP1TRPM8CHRM2CHRM1 | |
| SCHEMBL21114756 | 0.81 | TSHR (0.45) | POLBTDP1TRPM8CHRM2CHRM1 | |
| SCHEMBL6123009 | 0.81 | POLB (0.45) | POLBTDP1TRPM8ALDH1A1GAA | |
| Hydrochloric Acid SCHEMBL16762022 | 0.80 | POLB (0.44) | POLBTDP1TRPM8ALDH1A1GAA | |
| Hydrochloric Acid SCHEMBL6122436 | 0.80 | POLB (0.44) | POLBTDP1TRPM8ALDH1A1GAA | |
| SCHEMBL16762075 | 0.80 | ALDH1A1 (0.46) | POLBTDP1TRPM8CHRM2CHRM1 | |
| SCHEMBL6121764 | 0.80 | CTSK (0.46) | POLBTDP1TRPM8CHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190210992-A1 | AGONISTS THAT ENHANCE BINDING OF INTEGRIN-EXPRESSING CELLS TO INTEGRIN RECEPTORS | TEXAS HEART INSTITUTE (US) | 2019-07-11 | — | — | US | disclosed |
| US-10287264-B2 | Agonists that enhance binding of integrin-expressing cells to integrin receptors | TEXAS HEART INSTITUTE (US) | 2019-05-14 | — | — | US | disclosed |
| EP-3388429-A1 | AGONISTS THAT ENHANCE BINDING OF INTEGRIN-EXPRESSING CELLS TO INTEGRIN RECEPTORS | Texas Heart Institute (US) | 2018-10-17 | — | — | EP | disclosed |
| US-10071980-B2 | Agonists that enhanced binding of integrin-expressing cells to integrin receptors | TEXAS HEART INSTITUTE (US) | 2018-09-11 | — | — | US | disclosed |
| US-10035784-B2 | Agonists that enhanced binding of integrin-expressing cells to integrin receptors | TEXAS HEART INSTITUTE (US) | 2018-07-31 | — | — | US | disclosed |
| EP-2881392-B1 | Agonists that enhance binding of integrin-expressing cells to integrin receptors | TEXAS HEART INST (US) | 2018-06-06 | — | — | EP | disclosed |
| EP-2640721-B1 | AGONISTS THAT ENHANCE BINDING OF INTEGRIN-EXPRESSING CELLS TO INTEGRIN RECEPTORS | TEXAS HEART INST (US) | 2018-06-06 | — | — | EP | disclosed |
| EP-2881393-B1 | Agonists that enhance binding of integrin-expressing cells to integrin receptors | TEXAS HEART INST (US) | 2018-06-06 | — | — | EP | disclosed |
| US-20170044130-A1 | AGONISTS THAT ENHANCE BINDING OF INTEGRIN-EXPRESSING CELLS TO INTEGRIN RECEPTORS | TEXAS HEART INSTITUTE | 2017-02-16 | — | — | US | disclosed |
| US-9512109-B2 | Agonists that enhance binding of integrin-expressing cells to integrin receptors | TEXAS HEART INSTITUTE (US) | 2016-12-06 | — | — | US | disclosed |
| US-20150368234-A1 | AGONISTS THAT ENHANCED BINDING OF INTEGRIN-EXPRESSING CELLS TO INTEGRIN RECEPTORS | TEXAS HEART INSTITUTE | 2015-12-24 | — | — | US | disclosed |
| US-20150291571-A1 | AGONISTS THAT ENHANCED BINDING OF INTEGRIN-EXPRESSING CELLS TO INTEGRIN RECEPTORS | TEXAS HEART INSTITUTE | 2015-10-15 | — | — | US | disclosed |
| EP-2881393-A1 | Agonists that enhance binding of integrin-expressing cells to integrin receptors | Texas Heart Institute (US) | 2015-06-10 | — | — | EP | disclosed |
| EP-2881392-A1 | Agonists that enhance binding of integrin-expressing cells to integrin receptors | Texas Heart Institute (US) | 2015-06-10 | — | — | EP | disclosed |
| EP-2640721-A2 | AGONISTS THAT ENHANCE BINDING OF INTEGRIN-EXPRESSING CELLS TO INTEGRIN RECEPTORS | Texas Heart Institute (US) | 2013-09-25 | — | — | EP | disclosed |
| US-20130236434-A1 | AGONISTS THAT ENHANCE BINDING OF INTEGRIN-EXPRESSING CELLS TO INTEGRIN RECEPTORS | TEXAS HEART INSTITUTE (US) | 2013-09-12 | — | — | US | disclosed |
| WO-2012068251-A2 | AGONISTS THAT ENHANCE BINDING OF INTEGRIN-EXPRESSING CELLS TO INTEGRIN RECEPTORS | TEXAS HEART INSTITUTE (US) | 2012-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10035784-B2 | Agonists that enhanced binding of integrin-expressing cells to integrin receptors | ITGB7, ITGAL, ITGB1 | POLB 4149/4885TDP1 4720/4885TRPM8 559/4885 |
| US-20190210992-A1 | AGONISTS THAT ENHANCE BINDING OF INTEGRIN-EXPRESSING CELLS TO INTEGRIN RECEPTORS | ITGB7, ITGAL, ITGB1 | POLB 4239/4885TDP1 4768/4885TRPM8 639/4885 |
| US-20130236434-A1 | AGONISTS THAT ENHANCE BINDING OF INTEGRIN-EXPRESSING CELLS TO INTEGRIN RECEPTORS | ITGB7, ITGAL, ITGB1 | POLB 4210/4885TDP1 4738/4885TRPM8 520/4885 |
| US-10287264-B2 | Agonists that enhance binding of integrin-expressing cells to integrin receptors | ITGB7, ITGAL, ITGB1 | POLB 4210/4885TDP1 4738/4885TRPM8 520/4885 |
| US-20170044130-A1 | AGONISTS THAT ENHANCE BINDING OF INTEGRIN-EXPRESSING CELLS TO INTEGRIN RECEPTORS | ITGB7, ITGAL, ITGB1 | POLB 4210/4885TDP1 4738/4885TRPM8 520/4885 |
| US-20150291571-A1 | AGONISTS THAT ENHANCED BINDING OF INTEGRIN-EXPRESSING CELLS TO INTEGRIN RECEPTORS | ITGB7, ITGAL, ITGB1 | POLB 4149/4885TDP1 4720/4885TRPM8 559/4885 |
| US-20150368234-A1 | AGONISTS THAT ENHANCED BINDING OF INTEGRIN-EXPRESSING CELLS TO INTEGRIN RECEPTORS | ITGB7, ITGAL, ITGB1 | POLB 4149/4885TDP1 4720/4885TRPM8 559/4885 |
| US-10071980-B2 | Agonists that enhanced binding of integrin-expressing cells to integrin receptors | ITGB7, ITGAL, ITGB1 | POLB 4149/4885TDP1 4720/4885TRPM8 559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.